curasafehealthcare.com
  • Home
  • About
  • Services
  • Therapeutic Areas
  • Careers
  • Latest News
  • Contact Us
Select Page
Informed consent training for clinical research trials: online delivery

Informed consent training for clinical research trials: online delivery

by palligoelme@gmail.com | Mar 17, 2025 | Clinical Trials

​  Abstract This article describes how the South supra-region of the NIHR Clinical Research Network …  Abstract This article describes how the South supra-region of the NIHR Clinical Research Network … 
Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials

Hemogenyx Pharmaceuticals PLC Announces Recruitment of Second Patient for Clinical Trials

by palligoelme@gmail.com | Mar 17, 2025 | Clinical Trials

​    
Post-polio immune therapy aces human trials

Post-polio immune therapy aces human trials

by palligoelme@gmail.com | Mar 16, 2025 | Clinical Trials

​  Recent human trials of a new one-year-long immune-based treatment for post-polio syndrome, which can strike polio survivors years after the initial infection and be very debilitating, have produced positive results.  Recent human trials of a new one-year-long...
Novel cancer therapy works for 73 per cent Indian patients in clinical trials: Why the Lancet report is significant

Novel cancer therapy works for 73 per cent Indian patients in clinical trials: Why the Lancet report is significant

by palligoelme@gmail.com | Mar 16, 2025 | Clinical Trials

​  This is the first clinical trial of CAR T-cell therapy from India to be published in journal  This is the first clinical trial of CAR T-cell therapy from India to be published in journal 
Findings on Roflumilast Cream 0.05% for Children with Atopic Dermatitis, with Mercedes Gonzalez, MD

Findings on Roflumilast Cream 0.05% for Children with Atopic Dermatitis, with Mercedes Gonzalez, MD

by palligoelme@gmail.com | Mar 15, 2025 | Clinical Trials

​  This interview highlights recent findings on roflumilast cream 0.05% for patients aged 2 to 5 years with mild to moderate atopic dermatitis.  This interview highlights recent findings on roflumilast cream 0.05% for patients aged 2 to 5 years with mild to moderate...
Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer

Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer

by palligoelme@gmail.com | Mar 15, 2025 | Clinical Trials

​  Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients experienced disease recurrence during follow-up.  Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients...
« Older Entries
Next Entries »

Recent Posts

  • Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma
  • Safety, Tolerability, and Clinical Effectiveness of Adapalene/Clindamycin Phosphate Gel (Klenzit®-C) in Vietnamese Patients With Mild to Moderate Acne Vulgaris
  • A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)
  • Effect of Autologous Serum-Soaked Paper Patch vs. Traditional Dry Paper Patch on Tympanic Membrane Perforations
  • Use of cfDNA in Monitoring and Guiding Treatment for Cervical Cancer

Recent Comments

No comments to show.

Curasafe healthcare solutions Pvt. Ltd. provides comprehensive services including safety program oversight, risk management, and regulatory compliance.

Important Links

  • Home
  • Contact Us
Connect With Us

Contact


711, Shivalik Satyamev, Bopal Ambli Junction, Bopal, Ahmedabad, Daskroi, Gujarat, India, 380058.


info@curasafehealthcare.com



(+91) 97803 81065

Copyright © 2025 Curasafehealthcare ®